De Monitor - Pharming Professor schreef op 28 april 2021 10:57:
[...]
Helaas niet.
AM-Pharma is de willekeurige eerste die ik snel even heb opgezocht.
ROBUST STOP-AKI CLINICAL DATA WITH STRONG POSITIVE READ-THROUGH TO PIVOTAL TRIAL
To support regulatory approval from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), AM-Pharma is
now preparing for a large multinational Phase III pivotal study.
The US
FDA has granted Fast Track designation to recAP for the treatment of sepsis-associated AKI.
Pharming is net een Phase II begonnen.